Pharmaceuticals & Therapeutics

Vertero Therapeutics hits a critical clinical milestone, enrolling 24 patients in a Phase 1b trial of VT-5006 to target Parkinson's at its source in the gut.

With a new CEO and a $1.4 billion Novo Nordisk pact, Orbis Medicines leverages AI to transform injectable biologics into daily pills, expanding access.

RyCarma's Phase 2 trial for RYR1-RM offers the first clinical hope for a neglected community, testing a novel mechanism that could reshape muscle disease care.

Atom Therapeutics is pivoting its gout asset to tackle a 435-million-patient CKD market. Will lingdolinurad succeed where past URAT1 inhibitors failed?

Hansa Biopharma's enzyme therapy shows a 90% graft survival rate at one year, offering a vital lifeline to highly sensitized kidney patients ahead of FDA review.

A breakthrough in oral BTK inhibitors offers multiple sclerosis patients a highly effective treatment without the severe liver risks that doomed rival drugs.

Phase 3 data at ASN Kidney Week reveals lorundrostat's ability to lower blood pressure and albuminuria, positioning Mineralys for a pivotal FDA decision.

As ProKidney prepares to unpack new clinical data, we examine the strategic and commercial realities of bringing cell therapy to chronic kidney disease.

Scienture Holdings posted a 256% revenue jump on new drug launches, but scaling its tactical medical defense against synthetic opioids means beating a financial clock.

As traditional imaging gives way to ultrasensitive genomic data, Personalis is poised to disrupt the multi-billion dollar minimal residual disease market.

By programming stem cells into pancreatic beta cells in just four days, Syntax Bio is tackling the biomanufacturing choke point of Type 1 diabetes therapies.

A pending securities class action against Ardelyx highlights the growing collision between lofty biopharma revenue targets and the harsh reality of PBM cost controls.

As biotech valuations plummet, Yakira Capital is calling out Atrium's board over a highly dilutive $50 million raise. Is it time for a strategic review?

By appointing former Pfizer CSO Mikael Dolsten, Maxion Therapeutics signals its readiness to bring its revolutionary KnotBody platform into clinical trials.

Gesynta Pharma just shattered enrollment targets for its Phase 2 endometriosis trial. Here is why this signals a massive shift in biotech investment.

French biotech Adocia secures a €7M financing package, lifting its going-concern warning and bridging the gap to a crucial Chinese regulatory approval.

As antimicrobial resistance threatens global health, Paratek Pharmaceuticals leverages a $304 million BARDA contract to expand NUZYRA's clinical footprint.

As Chinese medicine seeks global credibility, a recent Singapore forum highlights the complex push to translate ancient theory into modern clinical guidelines.

Cyrano Therapeutics reports positive Phase 2 data for a repurposed asthma drug to treat post-viral smell loss, but regulatory hurdles loom for Phase 3.

Despite recent clinical setbacks, Alector's $75 million premium offering signals strong institutional faith in its blood-brain barrier technology.